The University Office That Licenses Inventions It Did Not Make
Federal legislation let universities own inventions from federally funded research. The technology transfer offices that followed produce a small number of enormous successes and a great many that never cover their costs.
The Legislation That Created the Industry
Before 1980, inventions arising from federally funded research generally belonged to the government, which held thousands of patents and licensed very few of them. Without exclusivity, no company would invest in developing an early stage discovery into a product.
The Bayh Dole Act permitted universities and other recipients to retain title to inventions made with federal funding, subject to obligations including disclosing the invention, filing for protection, giving preference to small business licensees, and manufacturing substantially in the United States for exclusive licensees.
The government retains a non exclusive licence for its own purposes and march in rights permitting it to compel licensing in defined circumstances, which have never been exercised despite periodic petitions.
What the Office Does
A technology transfer office receives invention disclosures from researchers, assesses commercial potential, decides whether to seek patent protection, markets the technology, negotiates licences, and administers royalties.
The decision to file is the expensive one. Patent prosecution across multiple jurisdictions costs tens of thousands of dollars per invention over years, spent before any licensee exists.
| Stage | Typical Attrition |
|---|---|
| Invention disclosures received | All |
| Patent applications filed | A minority |
| Licences executed | A minority of those |
| Licences producing meaningful revenue | A very small fraction |
The income distribution is more extreme than venture capital. A single successful drug patent can generate more than an entire university portfolio produces over a decade, which means the average outcome tells you nothing about the distribution.
The Economics Are Worse Than Assumed
The public perception is that technology transfer is a revenue source for universities. Analyses of the sector consistently find otherwise.
A substantial majority of offices do not cover their operating costs and patent expenses from licensing income. The ones that do are generally supported by one or two exceptional patents, frequently in life sciences.
The concentration is severe. Studies of licensing revenue across American universities find that a small number of institutions account for the large majority of income, and within those, a small number of inventions account for most of it.
That has produced a reasonable critique that offices optimising for revenue are pursuing a strategy that mathematically cannot work for most of them.
The Alternative Framing
The response from the sector is that revenue was never the primary purpose, and the more defensible measures are different.
Companies formed. University research generates startups, which create employment and attract investment regardless of what the university earns in royalties.
Products reaching the public. The purpose of the legislation was to get federally funded discoveries into use, and the count of approved drugs, devices, and technologies tracing to university research is substantial.
Regional economic development. Research clusters form around universities, and the local economic effect exceeds licensing income by orders of magnitude.
On those measures the system has performed well, and the revenue disappointment reflects a misunderstanding of what it was for.
The Friction With Researchers
The recurring complaint from faculty and from companies is that offices are slow, risk averse, and negotiate aggressively over inventions of uncertain value.
The dynamic is understandable from both sides. The office is negotiating on behalf of an institution that must treat all licensees consistently and cannot easily give away an asset that might be valuable. The researcher wants the technology used and frequently wants to found the company themselves.
Several institutions have responded with express licensing programmes offering standard terms with minimal negotiation for early stage technologies, on the reasoning that the expected value of most inventions does not justify months of negotiation.
Others have moved toward taking equity in spinouts rather than royalties, which aligns the institution with the company success and defers the cash.
The Revenue Sharing
Institutions share licensing income with inventors, typically under a published policy allocating a percentage to the inventor personally, with the remainder split between the department, the school, and central administration.
Inventor shares commonly range from a third to a half of net income. That is a substantial personal incentive and it is also the source of conflict of interest questions, particularly where a researcher has founded a company licensing their own invention and continues to conduct related research funded publicly.
Institutions manage this through conflict of interest committees, disclosure requirements, and in some cases prohibiting a researcher from directing research funded by a company they have an interest in.
The Bottom Line
Technology transfer exists because federally funded discoveries sat unused when the government owned them, and the legislation that fixed that created an office in every research university. The licensing income distribution is extreme enough that most offices lose money, which is a poor result if revenue was the objective and an acceptable one if the objective was getting inventions into use. The measures that actually justify the function are companies formed and products delivered, and the ones that get reported are royalties, which is why the sector is persistently misunderstood.